Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

prognosis

  • Prospective Phase II Trial of Prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy
    You have access
    Prospective Phase II Trial of Prognostication by 68Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy
    Esben Andreas Carlsen, Mathias Loft, Annika Loft, Anne Kiil Berthelsen, Seppo W. Langer, Ulrich Knigge and Andreas Kjaer
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 1371-1377; DOI: https://doi.org/10.2967/jnumed.121.263177
  • <sup>18</sup>F-FDG PET/CT–Based Prognostic Survival Model After Surgery for Head and Neck Cancer
    You have access
    18F-FDG PET/CT–Based Prognostic Survival Model After Surgery for Head and Neck Cancer
    Gwenaelle Creff, Franck Jegoux, Xavier Palard, Adrien Depeursinge, Ronan Abgral, Remi Marianowski, Jean-Christophe Leclere, Thomas Eugene, Olivier Malard, Renaud De Crevoisier, Anne Devillers and Joel Castelli
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 1378-1385; DOI: https://doi.org/10.2967/jnumed.121.262891
  • Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from <sup>68</sup>Ga-DOTATOC PET/CT in Well-Differentiated Neuroendocrine Tumors
    You have access
    Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from 68Ga-DOTATOC PET/CT in Well-Differentiated Neuroendocrine Tumors
    Philippe Thuillier, Virginia Liberini, Serena Grimaldi, Osvaldo Rampado, Elena Gallio, Bruno De Santi, Emanuela Arvat, Alessandro Piovesan, Roberto Filippi, Ronan Abgral, Filippo Molinari and Désirée Deandreis
    Journal of Nuclear Medicine July 1, 2022, 63 (7) 1014-1020; DOI: https://doi.org/10.2967/jnumed.121.262652
  • <sup>18</sup>F-FDG PET/CT for Posttreatment Surveillance Imaging of Patients with Stage III Merkel Cell Carcinoma
    You have access
    18F-FDG PET/CT for Posttreatment Surveillance Imaging of Patients with Stage III Merkel Cell Carcinoma
    Sonia Mahajan, Christopher A. Barker, Audrey Mauguen, Sandra P. D’Angelo, Randy Yeh and Neeta Pandit-Taskar
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 906-911; DOI: https://doi.org/10.2967/jnumed.121.262882
  • Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
    You have access
    Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
    Katherine A. Zukotynski, Urban Emmenegger, Sebastien Hotte, Anil Kapoor, Wei Fu, Amanda L. Blackford, John Valliant, François Bénard, Chun K. Kim, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis, Kenneth J. Pienta, Michael A. Gorin, Matthew Lubanovic, Jihyun Kim, Martin G. Pomper, Steve Y. Cho and Steven P. Rowe
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1430-1437; DOI: https://doi.org/10.2967/jnumed.120.259069
  • You have access
    18F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study
    Tina Binderup, Ulrich Knigge, Camilla Bardram Johnbeck, Annika Loft, Anne Kiil Berthelsen, Peter Oturai, Jann Mortensen, Birgitte Federspiel, Seppo W. Langer and Andreas Kjaer
    Journal of Nuclear Medicine June 1, 2021, 62 (6) 808-815; DOI: https://doi.org/10.2967/jnumed.120.244798
  • You have access
    Diagnosis, Treatment Response, and Prognosis: The Role of 18F-DOPA PET/CT in Children Affected by Neuroblastoma in Comparison with 123I-mIBG Scan: The First Prospective Study
    Arnoldo Piccardo, Giovanni Morana, Matteo Puntoni, Sara Campora, Stefania Sorrentino, Pietro Zucchetta, Martina Ugolini, Massimo Conte, Angelina Cistaro, Giulia Ferrarazzo, Marco Pescetto, Marco Lattuada, Gianluca Bottoni, Alberto Garaventa, Luca Giovanella and Egesta Lopci
    Journal of Nuclear Medicine March 1, 2020, 61 (3) 367-374; DOI: https://doi.org/10.2967/jnumed.119.232553
  • You have access
    Prognostic Value of 123I-BMIPP SPECT in Patients with Nonischemic Heart Failure with Preserved Ejection Fraction
    Hidenobu Hashimoto, Rine Nakanishi, Sunao Mizumura, Yukiko Hashimoto, Yuriko Okamura, Shunsuke Kiuchi, Junichi Yamazaki and Takanori Ikeda
    Journal of Nuclear Medicine February 1, 2018, 59 (2) 259-265; DOI: https://doi.org/10.2967/jnumed.117.195743
  • You have access
    18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma
    Mian Xi, Zhongxing Liao, Wayne L. Hofstetter, Ritsuko Komaki, Linus Ho and Steven H. Lin
    Journal of Nuclear Medicine November 1, 2017, 58 (11) 1756-1763; DOI: https://doi.org/10.2967/jnumed.117.192591
  • You have access
    Prognostic Value of Myocardial Perfusion Imaging with a Cadmium-Zinc-Telluride SPECT Camera in Patients Suspected of Having Coronary Artery Disease
    Elsemiek M. Engbers, Jorik R. Timmer, Mohamed Mouden, Siert Knollema, Pieter L. Jager and Jan Paul Ottervanger
    Journal of Nuclear Medicine September 1, 2017, 58 (9) 1459-1463; DOI: https://doi.org/10.2967/jnumed.116.188516

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
SNMMI

© 2025 SNMMI

Powered by HighWire